Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, October 23, 2026

Back to today

Research & Analysis: ERock, Inc. (NYSE: EROC)

ERock’s modular microgrids bridge data-center power gaps years before grid interconnects, with Meta and Anthropic projects filling capacity through early 2028.

EROC $453M
Monte Independent Investment Research 7 clicks

From X

@kevin__mak 3 clicks

Kevin Mak on X

$CORZ Some quick notes on this one. 1) In my view, CORZ has the most economically advantaged deal in the entire HPC industry. Their series of ~590mw of deals with CRWV was heavily tilted in their favor, and no deal after that has the same terms. 2) That deal is 70%+ finished construction, so there's no "if they get it built", it's largely built and should be fully built by early 2027. 3) According to CFO Jim Nygaard, the CRWV infrastructure cost $5.5B but would cost $7.5B to rebuild today, and CORZ holds the first lien. I call this a “capex put,” because IF there’s a problem with CRWV paying its contracts, CORZ has a claim on substantial infrastructure that could be re-leased to another customer. Depending on assumptions (discount rate, terminal value, etc), I see this as being worth $10-$13 per share in todays terms. They still have a ~530MW deal with AMD, plus another 1.5GW of "future expansion". The upside of CORZ is not the same as the other HPC/neocloud type plays. There's very little/no scenarios where I can see this stock going up by 5-10x. But the downside scenario is also very different. This is significantly less risky than its peers, yet, in this indiscriminate "vibes/basket" based market, it often trades very similarly. There lies the opportunity. When the market treats different assets as the same, because nobody cares about the nuance anymore. Positioning: I sold all of my shares between $20-$26 per share and thought I was done with CORZ forever. It's a pleasant surprise to be able to buy them back sub $15. Disclosure: Creek Drive and its affiliated funds holds positions in CORZ. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.

Investor Letters

All letters

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 26 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.5B
Latticework by MOI Global 4 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $108M
Triple S Special Situations Investing 4 clicks

Moon River Moly: Research Note

Moon River Moly’s updated Davidson PEA lifts after-tax NPV to $1.24 billion as flotation raises tungsten output 350% and cuts molybdenum…

MRIVF $16M
Atrium Research - Equity Research 4 clicks

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

GLOO $291M
Guardian Research 4 clicks
PYPD · long

Polypid LTD

PolyPid, an $80 million Israeli biotech, fell nearly 30% despite solving a clinical problem.

PYPD $103M
Value Investors Club

Why I sold OB pick for 26 SVM

Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite…

SVM $2B
The Oak Bloke 27 clicks

Vicor Update, Part Three

Vicor’s $66.6 million in AI power-delivery royalties generated about $50 million of operating profit, eclipsing its module business as…

VICR $8.1B
CV's Substack 28 clicks

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

CCLD $74M
Calvin Blissett 10 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 56 of 248

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.